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Both LFA-l-positive and -deficient T cell clones 
require the CD2/LFA-3 interaction for specific 
cytolytic activation*
We investigated the capacity of T lymphocytes from a leukocyte adhesion- 
deficient (LAD) patient to respond to alloantigen. Leukocytes of this patient 
completely lacked LFA-1 surface expression due to the absence of mRNA coding 
for the LFA-1 |3 chain. Despite the absence of LFA-1, T lymphocytes obtained 
from this patient, cultured with allogeneic stimulator cells (lymphoblastoid 
B cells JY), were capable of lysing JYcells. Furthermore, tw oT cell clones (one 
CD4+ and one CD8 +), generated from this lymphocyte culture, specifically lysed 
the allogeneic lymphoblastoid JY cells. The cytolytic capacity of LFA-1-negative 
T lymphocytes and T cell clones was comparable to that of control LFA-l- 
positive T cells with allospecificity against JY. Detailed analysis of the CD4 
positive and LFA-l-negative T  cell clone demonstrated that it specifically 
recognized HLA-DQ. Antibody inhibition studies showed that the CTL/target 
cell interaction was mediated through the CD2/LFA-3 adhesion pathway. LFA-1 
expressed by the target cells did not participate in the CTL/target cell conjugate 
formation and contributed only minimally to the cytotoxic activity. Moreover, 
when allogeneic LFA-l-deficient B cells, bearing the appropriate HLA-DQ 
alloantigen, were used as target cells, significant levels of specific cytotoxicity 
were measured, further excluding a role for LFA-1 in this interaction. The 
adhesion molecules, VLA-4, CD44 and L-selectin (LECAM1) were not 
involved.
These results demonstrate that LFA-l-negative T  lymphocytes can exert allo- 
specific cytotoxicity and that CTL/target cell contact is mediated through the 
CD2/LFA-3 route. This observation may explain in part why in LAD patients 
viral infections, cleared largely by T cells, are less frequently observed than 
bacterial infections, in which phagocytic ceils play a major role.
1 Introduction
Cell-cell interactions among leukocytes and of leukocytes 
with other cell types play an essential role in immune 
responses. Multiple cell surface receptors participate in cell 
adhesion including the glycoproteins that belong to the 
integrin or to the Ig supergene families [1-3]. LFA-1, CR3, 
andpl50,95 comprise a group of three integrins exclusively 
expressed by leukocytes. These heterodimeric adhesion 
molecules are each composed of a unique a  chain and share 
a common p chain, the p2 chain of the integrins [4]. Various 
studies demonstrate that the interaction of LFA-1 with its 
counterstructures ICAM-1 [5] and ICAM-2 [6] plays a 
major role in antigen-presenting cell/responder cell, and 
cytotoxic effector cell/target cell interactions [7-9]. The 
physiological importance of the LFA-1 receptor family is 
demonstrated in patients with a serious immunodeficiency
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syndrome, termed leukocyte adhesion deficiency (LAD). 
This disease is caused by the complete (severe type) or 
partial (moderate type) absence of cell surface expression 
of these adhesion receptor molecules [10-13]. The syn­
drome is characterized by recurrent and often fatal bacter­
ial infections, mainly due to decreased phagocyte functions 
and poor leukocyte mobilization [10, 14]. The rare reports 
of viral infections in these patients suggest that, they may 
be capable of evoking an immune response against viral 
pathogens, despite the absence of the P? integrins. These 
obervations suggest the involvement of other adhesion 
molecules in leukocyte function, such as: CD2 -  LFA-3, 
VLA-4, and L-selectin (LECAM 1) [15-18].
In this study we have investigated whether specific cyto­
toxic T lymphocytes can be generated from peripheral 
blood mononuclear cells of such LAD patients, and which 
adhesion routes are utilized in interaction of such CTL with 
target cells. The results demonstrate that cloned LFA-l- 
negative T cells are capable of exhibiting an alio specific 
cytotoxic response, and that this target cell adhesion is 
mediated through CD2 and LFA-3.
2 Materials and methods
2.1 T cell cultures
Peripheral blood lymphocytes of an LAD patient (VA) 
were isolated by centrifugation on FicollTsopaque. PBL
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were cloned by limiting dilution (5 x 104 -  0.5 cells/well) in 
round-bottom microtiter plates in 100 \i\ Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 5 % 
pooled human serum, I % antibiotic/myotic solution (Flow, 
Irvine, Scotland) and 0.2 % kanamycin solution (Sigma, St. 
Louis, MO). The LAD lymphocytes were stimulated with 
104 irradiated (50 Gy) allogeneic JY cells and 2 x 104 
irradiated (40 Gy) allogeneic lymphocytes per well from 
random donors, together with rIL-2 50 U/ml (Eurocetus, 
Amsterdam, The Netherlands) and 0.2 |xg/ml PHA. T ceil 
cultured in bulk (5 x 104 cells/well) and clones 
(0.5 cell/well) were expanded and restimulated once a week 
with this freshly prepared cell mixture together with rIL-2 
and PHA. Control clones and T cell cultures (EG) were 
generated and cultured under the same conditions. T cells 
had been cultured in bulk for 8-10 weeks. The CD 4- 
positive cytotoxic T cell clone, JS 136 was described 
previously [19] and specific recognized an HLA-DR deter­
minant exposed by JY cells.
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2.2 Cell lines
To determine the specificity of the immune responses the 
following EBV-transformed B lymphoblastoid cells were 
used: JY (HLA-: A2; B7; D Qw l,DQ w3; DR4,DRw6), 
LAD VA (HLA-: A3,A H ; B7,B51; D Q w l; D R 2), BA 
(HLA-: A24, A26; B7, B35; Cw3,Cw4; DQw3; DR4), MT 
(HLA-: A30,A31; Bw60; Cw3; DQw3; DR4; DPw4; 
Dwl4), H0301 (HLA-: A3; B14; Cw8 ; DQw6 ; DRw6 ; 
DPw5; Dwl9,Dw26), AWELLS (HLA-: A2; B44; Cw5; 
DQw7; DR4; DPw3,DPw4; Dw4), WIN (HLA-: A l; 
Bw57; Cw6 ; DQw2,DQw9; DR7; DPw4), APD (HLA-: 
A l; Bw60; DQw6 ; DRwl3; DPw4; Dwl8,Dw25). The 
LAD VA B cell line was established in our laboratory by 
EBV infection of B cells from LA D  patient (VA) and the 
BA B cell line by EBV infection of control B cells. The 
other EBV-transformed B cell lines were kindly provided 
by Drs. A. Termijtelen and F. Claas, University Hospital of 
Leiden, The Netherlands. To determine an allospecific 
cytotoxic activity against LA D  EBV-transformed B cells, 
four previously described LFA-l-negative B cell lines were 
used: AT, HS, CP, and MC [20]. The B cells and the 
MHC-negative erythroleukemia cells K562 were cultured in 
IMDM supplemented with 10 % FCS, 1 % antibiotic/myot­
ic solution and 0.2 % kanamycin solution. All cell lines were 
free of mycoplasma contamination.
2.3 mAb
For phenotypic analysis and for inhibition the functional 
capacity of the T cell clones the following m Ab were used: 
SPV-L7 (anti-LFA-1 a  chain, C D lla )  [21]; Bear-1 (anti- 
CR3 a  chain, C D llb ) [22]; SAM-1 (anti-VLA-5 a  chain, 
CD49e) [23]; SPV-T3b (anti-CD3) [24]; SPV-L3 (anti- 
HLA-DQ) [24]; NKI-P2 (anti-CD44) [25]. The following 
mAb were provided by several laboratories: CLB-LFA-1/1 
(anti LFA-1 common (3 chain, CD18) [26] and CLB-Tll/1 
(anti-CD2) [27], Dr. R. van Lier, Amsterdam,The Nether­
lands; CLB-10G11 (anti-VLA-2 a  chain, CDw49b) [28], 
C17 (anti~P3 chain, CD41) [29], Dr. A. von dem Borne, 
Amsterdam, The Netherlands; 4399.b (anti~(34 chain, 
CD61) [30], and GoH3 (anti-VLA -6 a  chain, CD49f) [31],
Dr. A. Sonnenberg, Amsterdam, The Netherlands; J143 
(anti-VLA-3 a  chain, CD49c) [32], Dr. E. Klein, Ulm, 
FRG; HP2/1, HP 1/2 (anti-VLA-4 a  chain, CD49d) [33], 
Dr. F. Sänchez-Madrid, Madrid, Spain; B-5G10 (auti- 
VLA-4 a  chain, CD49d) [34], Dr. M. Hemler, Boston, 
MA; TS2/9 (anti-LFA-3, CD58) [8] and TS2/16 (anti-ßx 
chain, CD29) [35], Dr. T. Springer, Boston, MA; AIIB2 
(anti-ßi chain, CD29) [36], Dr. C. Damsky, San Francisco, 
CA; K20 (anti-ßi chain, CD29) [37], Immunotech S.A., 
Marseille, France; RR1/1 (anti-ICAM-1, CD54) [38], Dr.T. 
Springer, Boston, MA; RIV-6 (anti-CD4) [39], Dr. F. 
UytdeHaag, Bilthoven, The Netherlands; WT82 (anti- 
CD8) [40], Dr.W.Tax, Nijmegen,The Netherlands; B-ly-6 
(anti-pl50/95 a  chain, CD llc) [41], Dr. S. Poppema, 
Edmonton, Canada; Leu-8 (anti-LECAMl) [18], Becton 
Dickinson, San Jose, CA.
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2.4 Nothern blot analysis
Total RNAwas extracted from 5 x 107 cloned LAD T cells 
and the control T cell clone, JS 136, according the guanid- 
nium isothiocyanate method [42]. Approximately 10 \ig/ 
sample of RNA was fractionated on a 1 % agarose gel 
containing formaldehyde. Ethidium bromide staining 
showed that comparable amounts of RNA from bothT cell 
clones were applied. RNA was blotted to a nitrocellulose 
membrane and the filter was hybridized at 65 °C in the 
presence of 10% dextran sulfate with a cDNA probe, 
recognizing the LFA-1 a  chain [43] and 32P-labeled by the 
random priming technique. The filter was washed twice in 
1 x SSC, 0.1 % SDS and once in 0.1 x SSC, 0.1 % SDS at 
65 °C and exposed to film overnight. Subsequently the filter 
was stripped in H2O at 95 °C, and hybridized with the 
32P-labeled cDNA probe which recognized the common P2 
chain [44]. Both cDNA probes were kindly provided by Dr. 
T. Springer, Boston, MA.
2.5 Flow cytometric analysis
Ceils were incubated with murine mAb at saturating 
concentrations for 30 min on ice, washed and stained with 
polyclonal goat anti-mouse F(ab ')2 antibody fragments 
coupled with FITC for another 30 min on ice. Samples were 
analyzed on a FACScan (Becton Dickinson, Mountain 
View, CA).
2.6 Cytotoxicity assay
One thousand labeled target cells (100 \x>Ci 51Cr/106 cells, 
Amersham Int., Amersham, GB) were incubated in V- 
bottom microtiter plates with various numbers of effector 
cells in 150 \i\ IMDM with 0.25 % BSA. The plates were 
centrifuged for 5 min at 50 x g and incubated at 37 °C and 
5 % CO2 during 4 h. After the incubation period 100 jliI of 
supernatant was collected from each well and counted in a 
gamma counter. All tests were carried out in triplicate. 
Specific lysis was determined as percentage of the net 
maximal 51Cr release by detergent. Spontaneous release in 
the absence of CTL was <25 % of maximal release by 
detergent in all experiments.
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2.7 Na-Benzyloxycarbonyl-L-lysine thiobenzy! ester 
(BLT) esterase secretion
T he BLT esterase secretion was determined as described by 
Spits et al. [45]. Cloned T cells (3 X 105) were mixed with 
equal numbers of target cells in a round-bottom well of 
microtiter plates in a total volume of 200 ¡ml IMDM with 5 % 
FCS and incubated at 37 °C and 5 % CO2 during 3 h. After 
incubation supernatants were harvested and BLT secretion 
was determined.The tests were performed in triplicate.The 
results were expressed as percentage of total net enzyme 
activity.
2 .8  T cell proliferation assay
Various numbers of cloned T cells were cultured in round- 
bottom  microtiter plates in 150 ml of IMDM with 5 % 
hum an serum in the presence of 5 x 104 irradiated (100 Gy) 
stimulator cells. After 72 h of co-culture at 37 °C and 5 % 
C O 2 each well was pulsed with 0.4 p,Ci of [3H] thymidine 
(New England Nuclear, Boston, MA) for 4 h, after which 
th e  DNA was collected using aTitertek multi well harvester 
an d  the incorporated radioactivity was counted.The results 
were presented as the mean cpm of triplicated cultures.
2 .9  Determination of heterotypic cell aggregation
Heterotypic cell aggregation was determined as described 
previously by Kuypers et al. [46]. T cell clones (2 x 106 
cells/ml) were labeled with 100 (xivr sulfofluorescein diace­
ta te  (SFDA), JY and K562 cells (2 x 106/ml) were labeled 
with hydroethidine (HE) 40 [xg/ml in a shaking water bath 
for 60 min at 37 °C. Labeled cells were washed three times 
and resuspended in IMDM with 10% FCS. Equal volumes
of labeled cells were mixed and incubated at room temper­
ature. After incubation the cells were fixed in paraformal­
dehyde (0.5 %) and the number of heterotypic cell aggre­
gation was measured in a FACScan (Becton Dickinson). 
The results were expressed as the percentage targets/effec­
tor conjugates of all analyzed particles containing target 
cells.
3 Results
3.1 Phenotype o f the LFA-l-negative T cell clones
Immunofluorescence analysis of 21 T cell clones derived 
from LAD patient VA showed that they lacked cell surface 
expression of the |32 integrin family, LFA-1, CR3 and 
p 150/95 (Table 1). This suggested a defect in expression of 
the common P2 chain. Northern blot analysis of steady- 
state mRNA isolated from an LAD T cell clone indeed 
indicated that mRN A encoding the P2 chain was completely 
absent, while it could readily be detected in an LFA-l- 
positive control clone (Fig. 1). LFA-Ia mRNA of this LAD 
clone, however, was expressed at a level comparable to that 
in the control clone (Fig. 1).
Futher examination of LAD T cell clones by immunofluor­
escence for expression of other integrins and a number of 
cell surface molecules, important for T  cell functions, 
revealed no difference between LAD T cell clones and 
control clones. Table 1 shows the results of 3 LAD clones 
out of 12 tested. Of the integrin family, only VLA-4 /¡3i 
complex was expressed at significant levels (Table 1). In 
addition, all 12 LA D  T cell clones expressed the a(3 T cell 
receptor and exhibited similar levels of the activation 
antigens CD25 (IL-2R) and CD45, and lacked Fey recep­
tors (data not shown).
T able  1, Antigen expression on cell surface of L A D  and control T  cell clones
Antigen mAb Fluorescence intensity51)
LAD 1.1 LAD 6.1 LAD 6,6 JS 136 EG D2
Control ► • 6 3 4 4 6
CDlla LFA-la SPV-L7 ' 5 : 4 3 449 360
CDllb CR3 Bear 1 6 6 4 55 39
CD 11c pl50,95 B-ly 6 4 3 4 3 11
CD 18 CLB-LFA-1/1 4 4 3 331 347
CDw49b VLA-2a 10 Gil 9 14 12 12 ; 16
CDw49c VLB-3 a J143 11 6 12 17 15
CDw49d VLA-4a HP2/1 '124 142 129 73 109
CD\v49e VL A-5 a SAMI 12 9 11 13 19
CD w49f VLA-6a GoIi3 13 9 8 7 14
CD29 Pi TS2/16 98 113 88 64 86
CD41 p3 C17 5 3 4 5 5
CD6Î IV 4399. b 4 3 2 3 ■; 7 <*
CD54 ICAM-1 RR1/1 ■ 47 . 38 29 24 42
CD 58 LFA-3 TS2/9 52 64 41 41 105
: CD 2 t CLB-T11/1 298 481 416 335 351
CD3 t SPV-T3b 308 499 360 290 305
CD4 ! * RIV-6 5 402 312 188 286
CDS WT82 485 7 :. - 5 8 7
CD 44 NKI-P2 323 421 162 259 363
LECAM1 Leu 8 1 7 8 5 9
a) Intensity of fluorescence 
reported  as mean chan­
nel intensity (arbitrary 
units).
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Figure 2. Specific cytotoxic activity of L A D  T cell clones ( - • -  
L A D  1,1, and L A D  6 .6), L A D  Tcells cultured in bulk (-A-), 
control T  cell clones ( -O -) ,  JS 136, and EG  D2), and control 
T cells  cultured in bulk ( - A - ) . Various concentrations of effector 
cells were added to 1 x  103 specific target cells (JY).
1 2  3 4
Figure 1. Northern blot analysis of LFA-1 a  and (3 chain expression 
in LAD and control T  cell clones. Total m R N A  was extracted from 
LAD 6.1, aT  cell clone lacking LFA-1 surface expression, th a t was 
generated from L A D  patient VA (lanes 1 and 3), and JS 136 an 
LFA-l-positive T  cell clone (lanes 2 and 4), generated from a 
healthy donor. LFA-1 transcripts were detected  by hybridization 
with 32P-labeled probes specific for the LFA-1 a  chain (lanes 1 and 
2), and for the common (3 chain (lanes 3 and 4),
3.2 Cytotoxic activity of LFA-l-negative T cells
We investigated the responsiveness of LAD T cells after 
stimulation with allogeneic EBV-transformed JY cells. 
LAD T cells, cultured in bulk, showed a cytotoxic capacity 
as high as control T cells (Fig. 2). Furthermore, 2 LAD 
T cell clones, out of 21 tested, showed cytolytic activity 
against JY, despite the absence of LFA-1. One of the clones 
was CD8+ (LAD 1.1), the other CD4+ (LAD 6 .6). The 
results in Fig. 2 demonstrate that the cytolytic activity of 
LAD T cell clones against the stimulator cells JY was 
similar to that of the control T cell clones (JS and Eg). No 
cytotoxic activity of both CD4+ T cell clones (LAD 6 .6 , JS 
136, and Eg D2) and the in bulk cultured T cells (LAD; 
control) against the nonspecific target K562 (the erythro- 
myeloid cells that lack H LA  class I and class II expression) 
could be observed, whereas the CD8+ T cell clone 
(LAD 1.1) exhibited low cytotoxic activity against K562 
(data not shown). To examine this LFA-l-independent 
cytotoxic activity and its specificity in more detail, we 
studied LAD 6 .6 , the CD4+ LAD T cell clone, since this 
clone showed the highest target specificity. The cytotoxic 
capacity of both clones (LAD 6.6  and the control clone JS 
136) could be inhibited by mAb against CD3 and CD4 
(Fig. 3A), indicating that the target cell is specifically 
recognized by theTcR. This notion is supported by the BLT 
serine esterase release which was observed after co- 
culturing of theT cells with JY cells but not with K562 cells
(Fig. 3B). Release of BLT serine esterase as a result of CTL 
degranulation is thought to be specially triggered by TcR 
ligation [45].
The lytic activity of LAD 6 .6 , but not that of the HLA-DR 
specificT cell clone JS 136 [19], could be inhibited by mAb 
specific for HLA-DQ suggesting that the cytolytic activity 
of LAD 6.6 is directed against a determinant on the 
HLA-DQ molecule (Fig. 3A). To analyze further the 
specificity of the T cell clone LAD 6.6 we used a panel of 
well-characterized EBV-transformed B cell lines. JY and 3 
other EBV-transformed B line cells out of 16 were lysed by 
LAD 6*6 and stimulated proliferation of LAD 6 .6 . (Fig. 4 
shows 6 B cell lines out of 16 tested). Out of the four lines 
recognized, three shared the HLA-DQw3 allotype. Again, 
lysis could be inhibited by addition of mAb against 
HLA-DQ but not by mAb against HLA class I (data not 
shown).
From these results we conclude that LAD T cell clones can 
exert specific cytotoxic activity in spite of the lack of the 
LFA-1 antigen at the cell surface,The LAD 6.6 T cell clone 
most likely recognized a determinant on the HLA-DQw3 
molecule.
3.3 Role of adhesion molecules in cytotoxicity
Blocking experiments with mAb demonstrated that the 
specific cytolytic activity of LAD 6.6 against the LFA-l- 
positive target cell, JY, could be inhibited (±55% ) by 
anti-LFA-3, anti-CD2 mAb, or by a combination of these 
mAb (Fig. 5). A combination of mAb against LFA-1 and 
ICAM-1 had only a minor inhibitory effect (22 %), caused 
by the fact that JYcells express normal levels of LIA.-1 and 
LAD 6.6 cells express ICAM-1. Blocking of both adhesion 
pathways caused an inhibition of the cytotoxic activity of 
83 %. Three mAb directed against VLA-4 a  chain (HP1/2, 
HP2/1, B-5G10), and three against the p chain (TS2/16, 
AIIB2, K20) of the integrin adhesion receptor which had 
previously been shown to participate in cytotoxic T cell 
interactions [47] were ineffective, despite the fact that some 
of them (HP1/2, and AIIB2) showed a high inhibitory effect
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Figure 3. Specific cytotoxicity of T  ccll clones 
L A D  6.6 (LFA-1 negative) and JS 136 (LFA-1 
positive) with the target cells (JY ).T h e  effector: 
target cell ratio was 30:1. (A ) Inhibition of 
cytotoxicity by m A b: purified IgG (10 |rg/ml) was 
present during the assay, in Ab against H L A  
class I (W6/32) was used as control mAb. O ne 
representative experim ent out of four is shown. 
(B) BLT serine esterase release from L A D  6.6 
and JS 136 after stim ulation with JY  cells and 
cells of the  erythrom yeloid cell line K562.
o n  VLA-4-mediated T cell adhesion to endothelial cells 
[48,49]. In addition, mixtures of anti-VLA-4 mAb with 
anti-CD2 and anti-LFA-3 or anti-LFA-1 and anti-ICAM-1 
m A b did not result in enhanced inhibition of lysis. Further,
cpm
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Figure 4. Response of LAD 6.6 T cell clone to  a panel of 
HLA-typed B cell lines and to autologous EBV-transformed 
B cells (LAD VA). (A) Proliferation of L A D  6.6 responder cells; 
various concentrations of responder cells were added to  5 x 104 
stimulator cells well. (B) Specific cytotoxicity of L A D  T cells; 
various concentrations of effector cell were added to 1 x 103 target 
cells/well.
mAb against CD44 were also ineffective (Fig. 5). Interest­
ingly, we found that even when LFA-1 is expressed on both, 
the effector cells (JS 136) and target cells (JY), the 
LFA-l/ICAM-1 adhesion pathway was subserved by the 
CD2/LFA-3 pathway in this allospecific cytotoxic activity 
(Fig. 5).
From these results we conclude that the CD2/LFA-3- 
mediated CTL/target cell interaction plays a prominent 
role in the TcR-mediated cytolytic process against JY cells 
for both, the LFA-l-negative and the LFA-1-positiveT cell 
clone. LFA-1 expressed o n T  cells seems less essential for 
this allospecific cytolytic interaction. Whereas LFA-1 
expressed on target cells may contribute to a minor ex­
tent.
3.4 Role of adhesion molecules in heterotypic conjugate 
formation
To examine the role of both adhesion pathways during the 
initial conjugate formation phase of the cytolytic process in 
more detail, we investigated binding of the T cell clones to 
specific target cells (JY). LAD 6.6  and JS 136 formed 
similar numbers of conjugates with the specific target JY 
(Fig. 6), Furthermore,we performed mAb blocking studies 
to determine which molecules participated in specific 
CTL/target cel! binding. mAb directed against CD3, CD4, 
and HLA-DQ did not inhibit conjugate formation (data not 
shown), confirming previous reports demonstrating that 
TcR-Ag/HLA interaction did not contribute significantly to 
the maintenance of cell/cell interaction*The results in Fig. 6 
show that anti-CD2  and anti-LFA-3 mAb completely 
blocked conjugate formation between LAD T cells and JY 
target cells. In contrast, blocking of conjugates of JS 136 
with JY cells was only obtained when the LFA-l/ICAM-1 
pathway was blocked simultaneously with the CD2/LFA-3 
pathway (Fig. 6), demonstrating that both adhesion path­
ways are involved.
These results support the conclusion that in specific target 
cell binding, both the CD2/LFA-3 and the LFA-l/ICAM-1
adhesion pathways are comparably involved. They act 
independently from each other and when one pathway is 
absent (LAD) or blocked by mAb (JS 136), the other 
adhesion route is sufficient to form conjugates.
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LAD 6.6 JS 136
JY Control 
LFA-1 + ICAM-1
CD2 
LFA-3 
CD2 + LFA-3
LFA-1 + ICAM-1 + CD2 + LFA-3
VLA-4
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Figure5. Inhibition of cytotoxic activity o f LFA -l-negative (LA D  6 .6) and LFA-l-positive (JS 136) T cell clones against allogeneic 
B cells JY. Purified IgG (10 \xg/mY) of each m A b was present in the assay except for anti-V LA -4 m A b and anti-CD44 mAb which were used 
in a dilution of 1/100 ascites fluid. m A b against M H C class I (W6/32) was used as control m A b.T he effector: target cell ratio was 30:1. One 
representative experiment: out of three is shown.
3.5 Role of LFA-1 expressed by the target cell in 
cytotoxicity
To determine further the contribution of LFA-1 expressed 
by the target cells, we investigated the cytotoxic capacity of 
the LFA-l-negative T cell clone (LAD 6 .6 ) against pre­
viously described, EBV-transformed B cells of four 
patients suffering from LAD [20]. Cells of one patient (Al) 
were lysed (Fig. 7A). The cells of this patient completely 
lack surface expression of LFA-1 [50]. Lysis of A l cells was 
blocked by mAb against FILA-DQ, CD3, and CD4 demon­
strating that HLA-DQ interaction withTcR/CD3 complex 
and CD4 was involved (Fig, 7B). Furthermore, mAb 
against the LFA-l/ICAM-1 adhesion pathway could not 
inhibit lysis of the target cells, whereas mAb blocking the 
CD2/LFA-3 adhesion pathway caused inhibition of lysis 
(Fig. 7B). All tested mAb against VLA-4a and (31 were 
were incapable of inhibiting lysis (data not shown). Allo- 
typing of A l cells revealed that the HLA-DQw3 is 
expressed, which explains specific recognition by LAD 6 .6 .
From these data we conclude that allospecific cytotoxic 
activity can exist without involvement of LFA-1.
4 Discussion
In the present study we have investigated the role of LFA-1 
/ICAM-1, CD2/ LFA-3, and other surface glycoproteins in 
the cytolytic activity of T  cell clones. Numerous studies 
have demonstrated that LFA-1 is particularly involved in 
the conjugate binding step that precedes lysis of the target, 
cells [3 ,7 -9 , 51]. Several investigations carried out with 
peripheral blood lymphocytes from LAD patients, whose 
leukocytes lack LFA-1 at the cell surface, demonstrate that 
T cell functions are impaired [52, 53], However, Mazerolles 
e ta l. [54] and Krensky et al. [55] showed that after 
repeated antigenic stimulation, T cells of LAD patients 
were capable of responding to alloantigen. Our results 
confirm and extend these observations, and show that 
T cells, and cloned T cells derived from peripheral blood of
LAD 6.6 JS 136
JY Control 
LFA-1 + ICAM-1 
CD2+ LFA-3
LFA-1 + ICAM-1 + CD2 + LFA-3
VLA-4
VLA-4 + LFA-1 + ICAM-1 
VLA-4+ CD2 +LFA-3
CD44
CD44 + LFA-1 + ICAM-1 
CD44 + CD2 + LFA-3
Conjugates (%)
Figure 6 , Inhibition by mAb of conjugate form ation of the T  cell clones L A D  6.6 (LFA-1 negative) and JS 136 (LFA-1 positive) with the 
allogeneic target B cells JY. Purified IgG  (5 fxg/ml) of each m A b was present in the assay, except for anti-VLA-4 mAb and anti-CD44 mAb 
which were used in a dilution of 1/200 ascites fluid. mAb against M HC class I (W6/32) was used as control mAb. L A D  T cells were 
incubated for 120 min with their targets, and JS 136 cells were incubated for 60 min. O ne representative experiment out of four is 
shown.
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S1
Cr release (%)
B Effector / Target cell
Control
MHC-DQ
CD3
CD4
LFA-1 + ICAM-1 
CD2 + LFA-3 
LFA-1 + ICAM-1 + CD2 + LFA-3
51
Cr release (%)
Figure 7. Specific cytotoxic activity of th e  LFA-l-negative T  cell 
clone, L A D  6.6 against LFA-l-negative EBV-transformed B cells. 
(A ) B cell lines of four patients with LA D . (B) m A b inhibition of 
cytotoxic activity of LFA-1 negative (L A D  6 .6) T  cell clones 
against allogeneic B cell AL Purified IgG (10 ¿ig/mi) of each mAb 
was present in the assay. mAb against M H C  class I (W6/32) was 
used as control mAb. The effector: target cell ratio was 3 0 :1. O ne 
representative experiment out of three is shown.
a severe type of LFA-l-deficient patient can exert high and 
specific cytolytic activity against allogeneic JY cells after 
repeated stimulation. The fact that the cytolytic activity of 
these T cells and T cell clones is similar to that of LFA-l- 
positive control T cells and T cell clones indicates that 
efficient lysis of allogeneic target cells can occur in the 
absence of LFA-1. We show that the adhesion of LAD 
T cells (LAD 6.6) to its target cells is mediated by 
CD2/LFA-3 interaction. Although the CD2 cell surface 
expression of LAD T cell clones was similar to that of 
LFA-l-positive T cell clones (Table 1), we can not com­
pletely exclude that selection occurred for T  lymphocytes 
with a high CD2 expression. However, the cloning frequen­
cy was similar to that of LFA-l-positive lymphocytes 
(±60% ) with an allospecific cytotoxic response of about 
10%. Furthermore, we show that LFA-l-negative B cells 
(Al) can be lysed in the complete absence of LFA-1, both 
on target and effector cells (Fig. 7). Even if LFA-1 is 
expressed on the target cells (JY), the contribution of the 
LFA-l/ICAM-1 interaction is limited. Since the allospecific 
LAD T cell clones were raised in the presence of LFA-l- 
positive JYcells, we can not completely rale out that LFA-1 
expressed by JY cells, played a role in the initiation of an 
immune response.
Our results are partially in contrast with those reported by 
Mentzer et al. [52] and Krensky et al. [55]. Mentzer et ah
have shown that LFA-1 expressed by the target cells 
significantly contributes to lysis by allospecific CTL, where­
as Krensky et al. have shown that anti-LFA-1 mAb partial­
ly inhibited the cytotoxic activity of bulk cultures of CTL 
derived from moderate and severe type of LAD patients in 
one case but not in another. However, the role of the 
CD2/LFA-3 adhesion pathway was not investigated in these 
studies. An explanation for the stronger dependency on the 
LFA-1 adhesion route in these experiments may be due to 
the fact that the T lymphocytes used in these studies were 
not absolutely deficient in LFA-1, or to differences in the 
level of cytotoxic activity of the lymphocytes of the various 
LAD patients.
In contrast with findings of Clayberger et al. [47], we were 
unable to demonstrate that VLA-4 is involved in lympho­
cyte cytotoxicity, although the anti-VLA-4 a  and anti-^1 
antibodies used effectively inhibit binding of T cells to acti­
vated endothelial cells [48, 56]. Furthermore, L-selectin 
(LECAM1) which is involved in homing of resting lympho­
cytes [18], is not involved in the cytolytic process since it is 
not expressed by cloned CTL. Finally the CD44 molecule 
that may participate in cell adhesion and lymphocyte 
homing [57], and is expressed at high levels on both 
LFA-l-negative and -positive CTL (Table 1), does not 
contribute to T  cell mediated cytotoxicity, despite the fact 
that anti-CD44 mAb can enhance homotypicT cell aggre­
gation [58].
Spits et al. [9] have shown that LFA-1 is particularly 
important in conjugate formation but does not seem to be 
involved in later phases of the cytolytic process such as 
delivery of the cytolytic hit. Our results now demonstrate 
that, at least for some lymphocytes, CTL/target interac­
tions can take place in the complete absence of LFA-1 on 
the CTL. In addition, analysis of the LFA-l-positive 
control T  cells also demonstrates that LFA-1 is not indisp­
ensable since CTL/target cell interactions could only be 
inhibited if both the LFA-l/ICAM-1 and LFA-3/CD2 
adhesion pathways are blocked.These observations suggest 
that, although LFA-1 may be of importance in the initiation 
of an immune response, at least in some cases, antigen- 
specific CTL can bind and lyse their target cells in an 
LFA-l-independent manner. Possibly the enhanced expres­
sion of CD2, as reported on memory and activated 
peripheral T lymphocytes by Sanders et al. [59] may 
explain why binding of targets, by these activated cells, 
depends less on the LFA-l/ICAM-1 pathway.
Our results indicate that specific lysis, not only by LFA-1 - 
deficient, but also by the LFA-l-positive CTL used in this 
study, is primarily mediated by the CD2/LFA-3 adhesion 
pathway, whereas the LFA-l/ICAM-1 adhesion pathway is 
subserved (Fig. 5). In conjugate formation, however, 
between specific LFA-l-positive CLTand target cells, both 
the LFA-l/ICAM-1 and the CD2/LFA-3 adhesion route are 
involved. In the absence of LFA-1 (LAD) or after blocking 
one route by mAb, CTL/target cell binding  is regulated by 
the other adhesion pathway (Fig. 6).
Although LAD patients suffer frequently from severe 
bacterial infections, that are probably due to impaired 
migration and phagocytosis by macrophages and granulo­
cytes, only two cases of unusually severe viral infections 
have been reported [14].These observations together with
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our findings support the notion that T cells in such patients 
can at least partially compensate for the LFA-1 defect. The 
results of this study show that cytolytic activity can occur 
after CTL/target cell binding mediated via the CD2/LFA-3 
adhesion route whereas other observations show that 
VLA-4/VCAM interaction mediates binding of LAD Tand 
B cells to activated endothelium [56, 60]. These observa­
tions indicate that a lymphocyte seems better equipped 
with supplementary adhesion receptors than myelomono- 
cytic cells, that apparently lean heavily on the three 
receptors comprising the LFA-1 family to migrate and to 
carry out their function [10, 14].
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